These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33469316)

  • 21. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
    Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
    Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis.
    Zoumot Z; Al Busaidi N; Tashkandi W; Aljohaney AA; Isse S; Vidyasagar K; Ukwaja KN
    J Asthma Allergy; 2022; 15():1665-1679. PubMed ID: 36425526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tezepelumab in patients with allergic and eosinophilic asthma.
    Caminati M; Buhl R; Corren J; Hanania NA; Kim H; Korn S; Lommatzsch M; Martin N; Matucci A; Nasser SM; Pavord ID; Domingo C
    Allergy; 2024 May; 79(5):1134-1145. PubMed ID: 38146651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR study.
    Menzies-Gow A; Bourdin A; Chupp G; Israel E; Hellqvist Å; Hunter G; Roseti SL; Ambrose CS; Llanos JP; Cook B; Corren J; Colice G
    Ann Allergy Asthma Immunol; 2023 Sep; 131(3):343-348.e2. PubMed ID: 37263380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
    Ly N; Zheng Y; Griffiths JM; van der Merwe R; Agoram B; Parnes JR; Roskos L
    J Clin Pharmacol; 2021 Jul; 61(7):901-912. PubMed ID: 33368307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
    Wechsler ME; Menzies-Gow A; Brightling CE; Kuna P; Korn S; Welte T; Griffiths JM; Sałapa K; Hellqvist Å; Almqvist G; Lal H; Kaur P; Skärby T; Colice G;
    Lancet Respir Med; 2022 Jul; 10(7):650-660. PubMed ID: 35364018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.
    Roy P; Rafa ZI; Haque SN; Tasha T; Arko SB; Agrawal H; Razu MI; Parisapogu A; Maisha S; Siddique MA; Abbasi FK; Shama N; Dev Nath S; Ghosh AS; Quader F
    Cureus; 2022 Dec; 14(12):e32156. PubMed ID: 36601189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
    Corren J; Garcia Gil E; Griffiths JM; Parnes JR; van der Merwe R; Sałapa K; O'Quinn S
    Ann Allergy Asthma Immunol; 2021 Feb; 126(2):187-193. PubMed ID: 33169672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of action of tezepelumab (TEZSPIRE
    Niu M; Yabuta T; Makita N
    Nihon Yakurigaku Zasshi; 2024; 159(1):53-60. PubMed ID: 38171840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
    Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
    J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study.
    Shinkai M; Ebisawa M; Fukushima Y; Takeuchi S; Okada H; Tokiyo T; Hayashi N; Takikawa M; Colice G; Almqvist G
    J Asthma; 2023 Mar; 60(3):616-624. PubMed ID: 35707873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma.
    Matera MG; Ora J; Rogliani P; Cazzola M
    Expert Opin Drug Discov; 2023; 18(9):951-963. PubMed ID: 37387523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.
    Korn S; Cook B; Simpson LJ; Llanos JP; Ambrose CS
    Adv Ther; 2023 Jul; 40(7):2944-2964. PubMed ID: 37233876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis.
    Shaban Abdelgalil M; Ahmed Elrashedy A; Awad AK; Reda Gad E; Ali MM; Abdelmoez Farahat R; Hassan Shawki B; Abd-ElGawad M
    Sci Rep; 2022 Dec; 12(1):20905. PubMed ID: 36463281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic Modeling and Exposure-Efficacy and Body Weight-Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma.
    Zheng Y; Abuqayyas L; Quartino A; Guan Y; Gao Y; Liu L; Hellqvist Å; Colice G; MacDonald A
    J Clin Pharmacol; 2024 Aug; 64(8):908-921. PubMed ID: 38632826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positioning of Tezepelumab in Severe Asthma.
    Miralles-López JC; Antolín-Amérigo D; García-Moguel I; Domínguez-Ortega J; Delgado-Romero J; Quirce S
    J Investig Allergol Clin Immunol; 2024 Feb; 34(1):1-11. PubMed ID: 37812191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tezepelumab in the Treatment of Uncontrolled Severe Asthma.
    Feist J; Lipari M; Kale-Pradhan P
    Ann Pharmacother; 2023 Jan; 57(1):62-70. PubMed ID: 35535458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
    Shinkai M; Yabuta T
    Immunotherapy; 2023 Dec; 15(17):1435-1447. PubMed ID: 37724378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.